Inspira to Unveil HYLA™ Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed

Core Insights - Inspira Technologies is set to unveil its HYLA blood sensor at the U.S. ELSO Annual Conference, marking its first presentation to the global medical community [1][2] - The HYLA sensor has demonstrated a performance accuracy of 97.35% compared to standard blood gas analyzers, positioning it as a significant advancement in medical technology [2] - The ELSO conference serves as a strategic platform for Inspira to engage with leading clinicians and industry leaders, facilitating discussions on commercialization and partnerships for the HYLA platform [3] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its FDA-cleared ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5] - The company is developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake and breathing spontaneously [5] - Inspira is advancing its proprietary HYLA blood sensor platform, which offers continuous, non-invasive monitoring, and is positioned as an attractive player in the life-support and MedTech landscape [5]